Spotlight on ixazomib: Potential in the treatment of multiple myeloma

Barbara Muz, Rachel Nicole Ghazarian, Monica Ou, Micah John Luderer, Hubert Daniel Kusdono, Abdel Kareem Azab

Research output: Contribution to journalReview articlepeer-review

89 Scopus citations


Despite the significant therapeutic advances achieved with proteasome inhibitors (PIs) such as bortezomib and carfilzomib in prolonging the survival of patients with multiple myeloma, the development of drug resistance, peripheral neuropathy, and pharmacokinetic limitations continue to pose major challenges when using these compounds. Ixazomib is a second-generation PI with improved activity over other PIs. Unlike bortezomib and carfilzomib, which are administered by injection, ixazomib is the first oral PI approved by US Food and Drug Administration. This review discusses the biochemical properties, mechanisms of action, preclinical efficacy, and clinical trial results leading to the US Food and Drug Administration approval of ixazomib.

Original languageEnglish (US)
Pages (from-to)217-226
Number of pages10
JournalDrug Design, Development and Therapy
StatePublished - Jan 11 2016
Externally publishedYes


  • Biological mechanism
  • Clinical trials
  • Oral administration
  • Proteasome inhibitor

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science
  • Drug Discovery


Dive into the research topics of 'Spotlight on ixazomib: Potential in the treatment of multiple myeloma'. Together they form a unique fingerprint.

Cite this